Endostatin in Combination with PD-1 Antibody Plus Chemotherapy As First-Line Regimen for EGFR/ALK-negative, Advanced or Metastatic Non-Small Cell Lung Cancer: A Real-World Study
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要